US Healthcare Ishares ETF (IYH)

While Danaher has considerably trailed behind the broader market over the past 52 weeks, Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.

Although Humana has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...

IDEXX Laboratories has significantly outperformed the broader market in recent months, and analysts remain cautiously optimistic about the stock’s prospects.

Despite Regeneron Pharmaceuticals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Abbott Laboratories is expected to announce its first-quarter results this month, and analysts predict a single-digit growth in the company’s bottom-line figure.

President Trump's reciprocal tariffs have weakened U.S. consumer and business sentiment, as consumers grow uncertain about the 'chaotic' U.S. policy, according to Reuters.Global growth concerns have resurfaced...

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.